Industry P Pharmaceutical Commerce
How the GLP-1 Boom Stress-Tests the Pharma Cold Chain
GLP-1 demand is straining pharma cold chain capacity, from tighter temperature thresholds and rising load rejections to fuel costs and trailer backlogs.
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry P Pharmaceutical Commerce
GLP-1 demand is straining pharma cold chain capacity, from tighter temperature thresholds and rising load rejections to fuel costs and trailer backlogs.
Industry
BioSpace
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Industry
European Biotechnology
In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a patent application once the claims are deemed allowable. The adaptation of the description is an extensive and very costly writing exercise. There was inc…
Industry P Pharmafile
bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem cell (iPSC)-derived cardiomyocytes for drug discovery and safety testing. The partnership gives researchers access to ventricular and atrial cardiomyocytes, alon…
Industry S Science News
Optical illusions trick enemies into misjudging the insects’ speed and direction
Industry P Pharmaceutical Executive
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Industry P Pharmaceutical Executive
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Industry
STAT Biotech
“The surest way to secure our biotech lead is to build up our own capabilities,” write Gary Locke and Patrick McHenry.
Industry
European Biotechnology
uniQure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical significance on the main disease progression measure after four years. The Dutch biotech reported continued slowing of decline with AMT-130, but the update comp…
Industry S Science News
How politics, bad timing, and skepticism left foundation stones of modern physics unrecognized
Industry I In the Pipeline
I'll be taking the rest of this week and all of next week off (catching up on some things and recharging my batteries in general) Posting will resume on Monday the 12th, and I'll see everyone then!
Industry
BioSpace
It’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.
Industry
BioSpace
It’s not enough for organizations to want scientists to think like entrepreneurs. They have to incentivize and reward for that behavior.
Industry
BioCentury
BIOCENTURY | DATA BYTEI-DXD WITHDRAWAL THINS OCTOBER PDUFA CALENDARFive FDA decisions remain after BLA withdrawal and two sNDA approvals
Industry
BioCentury
BIOCENTURY | DEALSNOVO GETS SHOT AT WEEKLY OBESITY PILL AS HENGRUI GETS ANOTHER MNC DEALNovo adds once-weekly oral GLP1R/GIPR dual agonist for $300M up front
Industry
BioCentury
BIOCENTURY | POLITICS, POLICY & LAWBEAM LAWSUIT ACCUSES YOLTECH AND SERAPHA OF TECH THEFTYolTech CEO ‘categorically rejects’ accusations
Industry
Nature Reviews Drug Discovery
Industry
Inside Precision Medicine
First-in-class triple agonist retatrutide produced nearly 19% average weight loss in people with obesity and type 2 diabetes, a population historically harder to treat. The post Triple Agonist Retatrutide Pushes Weight Loss to New Levels in Type 2 Diabetes appeared first on Insid…
Industry B BioPharm International
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Industry
MedCity News
AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug com…
Industry P Pharmaceutical Executive
New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeuti…
Industry
BioPharma Dive
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
Industry
STAT Biotech
The gene-editing company Beam Therapeutics is alleging that one of its scientists stole intellectual property and used it to co-found a Chinese company that made a deal with VC firms.
Industry A Applied Clinical Trials
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
Industry
GEN
The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate selection. The post Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Cons…
Industry B BioPharm International
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
Industry
Drug Discovery and Development
After more than a year of threats and six months after President Donald Trump signed a national-security proclamation, U.S. tariffs on imported patented medicines and their ingredients expanded Sept. 29 to mid-sized and smaller drugmakers that were left off the first company list…
Industry
BioPharma Dive
The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.
Industry
Fierce Pharma
From Data Rich to Decision Ready in Life Sciences pesurya Tue, 09/29/2026 - 11:39
Industry
BioPharma Dive
Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."
Industry
GEN
Chemotherapies frequently cause cancer cells to enter senescence, but do not fully eliminate these cells. Therefore, it is useful to target these therapy-induced senescent cells with senolytics that eliminate them. The post How Cells Respond Differently to a Cancer-Causing Gene a…
Industry
Fierce Biotech
There Is No Such Thing as a Typical Biotech pesurya Tue, 09/29/2026 - 11:06
Industry
TechCrunch Biotech and Health
Uhura Bionics, part of the Startup Battlefield 200 at TechCrunch Disrupt, wants to replace flat, robotics voice devices with one that carries emotions.
Industry P Pharmaceutical Executive
Pharma CFOs are navigating an increasingly complex business environment. From portfolio investments and pricing pressure to manufacturing strategy and AI adoption, the pace and stakes of decision-making continue to rise. The organizations pulling ahead are the ones that rely on f…
Industry
Labiotech
Take a look at some of the top biotech companies you can find in Spain, whose biotech industry has grown dramatically in the last decade. The post Nine biotech companies you should know about in Spain appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized u…
Industry P Pharmaceutical Executive
Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs.
Industry B BioPharm International
Ivonescimab, in phase 3 trials across 8 tumor types, will be paired with sonesitatug vedotin in new gastrointestinal cancer trials.
Industry P Pharmaceutical Commerce
As more pharmacies dispense GLP-1s, payment processor reviews, higher fees and account closures are emerging as an overlooked point of friction in the access channel.
Industry
MedTech Dive
Former ZimVie CFO Richard Heppenstall fills the vacancy created by the departure of Leo Greenstein, who is leaving Carlsmed to pursue other professional interests.
Industry P PLOS Biology
by Jie Ren, Yu Sang, Young-Mo Kim, Ernesto S. Nakayasu, Alejandro Aballay Animals must allocate limited energetic resources across competing defense programs in response to infection. Here, we show that the conserved nuclear hormone receptor NHR-68 integrates fatty acid metabolis…